You are here

AstraZeneca's immunotherapy drug wins key lung cancer approval

BT_20180219_NVASTRA19Y9SP_3313602.jpg
The approval for AstraZeneca's immunotherapy drug opens up a multibillion-dollar market for a medicine that has until now lagged behind competitors.

London

ASTRAZENECA'S immunotherapy drug Imfinzi has won crucial approval from US regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

The US Food and Drug Administration said late on Friday that it

sentifi.com

Market voices on:

Powered by GET.comGetCom